London · Delayed Price · Currency is GBP · Price in USD Esperion Therapeutics Statistics
Total Valuation
LON:0IIM has a market cap or net worth of GBP 587.62 million. The enterprise value is 960.94 million.
| Market Cap | 587.62M |
| Enterprise Value | 960.94M |
Important Dates
The next estimated earnings date is Tuesday, March 3, 2026.
| Earnings Date | Mar 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 235.43M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +18.70% |
| Shares Change (QoQ) | +1.61% |
| Owned by Insiders (%) | 0.91% |
| Owned by Institutions (%) | 44.58% |
| Float | 221.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 9.73 |
| PS Ratio | 2.60 |
| PB Ratio | -1.75 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.21 |
| EV / Sales | 4.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.00
| Current Ratio | 1.00 |
| Quick Ratio | 0.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.37 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -5.42% |
| Return on Invested Capital (ROIC) | -10.83% |
| Return on Capital Employed (ROCE) | -589.13% |
| Weighted Average Cost of Capital (WACC) | 10.12% |
| Revenue Per Employee | 743,455 |
| Profits Per Employee | -258,987 |
| Employee Count | 304 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 1.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +93.28% in the last 52 weeks. The beta is 1.04, so LON:0IIM's price volatility has been similar to the market average.
| Beta (5Y) | 1.04 |
| 52-Week Price Change | +93.28% |
| 50-Day Moving Average | 3.59 |
| 200-Day Moving Average | 2.34 |
| Relative Strength Index (RSI) | 50.17 |
| Average Volume (20 Days) | 45,517 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.91 |
Income Statement
In the last 12 months, LON:0IIM had revenue of GBP 226.01 million and -78.73 million in losses. Loss per share was -0.40.
| Revenue | 226.01M |
| Gross Profit | 98.12M |
| Operating Income | -21.86M |
| Pretax Income | -78.73M |
| Net Income | -78.73M |
| EBITDA | -21.78M |
| EBIT | -21.86M |
| Loss Per Share | -0.40 |
Balance Sheet
The company has 68.78 million in cash and 447.10 million in debt, with a net cash position of -378.32 million.
| Cash & Cash Equivalents | 68.78M |
| Total Debt | 447.10M |
| Net Cash | -378.32M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -335.79M |
| Book Value Per Share | -1.63 |
| Working Capital | 1.06M |
Cash Flow
| Operating Cash Flow | -69.40M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 43.42%, with operating and profit margins of -9.67% and -34.84%.
| Gross Margin | 43.42% |
| Operating Margin | -9.67% |
| Pretax Margin | -34.84% |
| Profit Margin | -34.84% |
| EBITDA Margin | -9.64% |
| EBIT Margin | -9.67% |
| FCF Margin | n/a |
Dividends & Yields
LON:0IIM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.70% |
| Shareholder Yield | -18.70% |
| Earnings Yield | -13.40% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0IIM has an Altman Z-Score of -5.65 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.65 |
| Piotroski F-Score | 2 |